Company news

KORU Medical Systems, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

June 3, 2024

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

May 13, 2024

KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

April 30, 2024

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

April 16, 2024

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

April 10, 2024

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

March 17, 2024

KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance

March 12, 2024

KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic

March 10, 2024

KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin

March 5, 2024

KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

February 20, 2024

KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference

November 28, 2023

KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023

November 27, 2023

KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

November 7, 2023

KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System

November 7, 2023

KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook

November 7, 2023

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes

November 6, 2023

KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023

October 24, 2023

KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference

October 4, 2023

KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

October 3, 2023

KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase

September 14, 2023

KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook

August 8, 2023

KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference

August 7, 2023

KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates

August 1, 2023

KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023

July 30, 2023

KORU Medical Systems Announces Novel Therapies Collaboration for Late-Stage Endocrinological Biologic

July 26, 2023

KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes

July 9, 2023

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

June 26, 2023

KORU Medical Systems, Inc. Announces 2023 First Quarter Financial Results

May 3, 2023

KORU Medical Systems to Report First Quarter Financial Results on May 4, 2023

April 20, 2023

KORU Medical Systems Announces 2022 Q4 and Full Year Financial Results, Accelerating to 19% Revenue Growth in 2022

March 7, 2023

KORU Medical Systems to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

February 21, 2023

KORU Medical Systems Announces Subcutaneous Immunoglobulin Prefilled Syringe Development Agreement

January 24, 2023

KORU Medical Systems to Participate in the Piper Sandler 34th Annual Healthcare Conference

November 20, 2022

KORU Medical Systems Announces 2022 Third Quarter Financial Results

November 8, 2022

KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals

November 7, 2022

KORU Medical Systems to Report Third Quarter 2022 Financial Results on November 9, 2022

October 25, 2022

KORU Medical Systems to Participate in Upcoming Industry Conferences

October 16, 2022

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

October 11, 2022

KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium

October 4, 2022

KORU Medical Systems to Participate in Canaccord Genuity's 42nd Annual Growth Conference

August 3, 2022

KORU Medical Systems Announces 2022 Second Quarter Financial Results

August 2, 2022

KORU Medical Systems to Report Second Quarter 2022 Financial Results on August 3, 2022

July 19, 2022

KORU Medical Systems Announces 2022 First Quarter Financial Results

May 3, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of EMPAVELI® (pegcetacoplan), Expands European Label for FreedomEdge®

May 1, 2022

KORU Medical Systems to Report First Quarter 2022 Financial Results on May 4, 2022

April 19, 2022

KORU Medical Systems Appoints Brian Case As Chief Technology Officer

April 17, 2022

KORU Medical Systems Announces 2021 Q4 and Full Year Financial Results

March 1, 2022

CORRECTING and REPLACING KORU Medical Systems to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

February 15, 2022

KORU Medical Systems Receives FDA 510(k) Clearance for the Use of the FREEDOM60® with Two Additional SCIg Drugs

December 20, 2021

KORU Medical Systems to Unveil Updated Strategic Plan at Investor Day

November 30, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.